July 11, 2025 5:12pm

Showering share pricing collateral damage to the July’s cell and gene therapy sector positive closes; Friday’s losses highlight earnings season before it even begins

Although I saw/felt a crash coming from Wednesday’s a.m.’s post, ““Uncle algo and his electronic trading dwarfs” are hovering, drooling in anticipation and direction”

News: Moderna (MRNA) reports Q2 earnings on Friday, 8/1

I say what others won’t, so you can do what others can’t!

I also try to answer as many whys, as I can … while providing the metrics to validate my thesis

Never leave an investor uninformed!  

My perspective is retail investors are just rolling-the-dice until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

RegMed Investors’ (RMi) pre-open: When markets and sector go this high, I surmise lower … https://www.regmedinvestors.com/articles/13993

Thursday night’s RegMed Investors (RMi) Closing Bell: Some cooling yet, sector stays within an upside course … https://www.regmedinvestors.com/articles/13992

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Friday: The Dow closed DOWN -279.13 points or -0.63%, the S&P closed DOWN -20.71 points or -0.33% while the Nasdaq closed DOWN -45.14 points or -0.22%

  • Theme of the session, an escalating trade battle
  • For the week, the Dow declined -1%, the S&P -0.03% and the Nasdaq -0.01

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • President Trump announced a 35% tariff on Canada and threatened higher tariffs across the board; citing fentanyl as a reason for higher Canada duties, adding that they would go higher if the country retaliates.

Friday’s advance/decline line opened negative with 22 incliners, 10 decliners and 3 flats ending with a negative close of 5 incliners, 28 decliners and 2 flats    

Metrics:  Friday, the IBB was down -1.64%, the XBI was down -0.96% while the VIX was UP +0.62 points or +3.93% at 16.40

 

Q3 – 7/25 – 1 market holiday, 6 positive and 2 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Friday Closing UP (5 of 5) 

  • Agenus (AGEN +$1.14 after Thursday’s +$0.74),
  • Lenz Therapeutics (LENZ +$0.43 after Thursday’s -$0.56, Wednesday’s +$3.46,Tuesday’s -$0.12 and Monday’s -$1.11),
  • Mesoblast (MESO +$0.09 after Thursday’s +$0.51),
  • Sage Therapeutics (SAGE +$0.06),
  • Generation Bio (GBIO +$0.0135)

Flat (2)

  • bluebird bio (BLUE) P/E acquired
  • Homology Medicine (FIXX)

Friday’s Closing DOWN (10 of 28): 

  • Alnylam Pharmaceuticals (ALNY -$7.70 after Thursday’s +$1.77 after Wednesday’s +$3.32, Tuesday’s -$6.63 and Monday’s -$7.78),
  • CRISPR Therapeutics (CRSP -$2.20 after Thursday’s -$1.08, Wednesday’s+$5.28, Tuesday’s+$3.62 and Monday’s -$0.980,
  • Ultragenyx Pharmaceuticals (RARE -$1.52 after Thursday’s -$10.40, Wednesday’s +$2.00 and Tuesday’s -$0.19),
  • Vericel (VCEL -$1.30 after Thursday’s -$0.27, Wednesday’s +$1.26, Tuesday’s +$0.76 and Monday’s -$2.33),
  • Beam Therapeutics (BEAM -$0.87 after Thursday’s +$0.57, Wednesday’s +$1.17, Tuesday’s +$1.11 and Monday’s -$0.83),
  • BioLife Solutions (BLFS -$0.77 after Thursday’s +$0.39, Wednesday’s -$0.23, Tuesday’s +$0.74 and Monday’s -$1.03),
  • Ionis Pharmaceuticals (IONS -$0.65 after Thursday’s -$0.45, Wednesday’s +$1.48 after Tuesday’s -$0.46 after Monday’s -$1.22)
  • Moderna (MRNA -$0.64 after Thursday’s +$1.49),
  • Intellia Therapeutics NTLA -$0.62),
  • uniQure NV (QURE -$0.48),

 

The BOTTOM LINE:  Indexes toed the trip wire … while small caps lagged a generally down-market Friday as the Russell 2000 (-1.3%), the S&P (-0.03%), Nasdaq (-0.02%) and Dow (-0.06) were responsible for most of the selling.

  • Declining stocks beat advancers on the Nasdaq by nearly 3-to-1. The ratio was also 3-to-1 negative on the NYSE
  • Volume was decidedly lower on both exchanges compared with the same time Thursday, in preliminary numbers

Cell and gene therapy sector equities on Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday

  • After last week popping multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

As I also wrote, the “June Swoon” is over … however, July will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

Last session of June as July evolves ‘25: understand the “flow” …

  • 7/11 - Friday closed negative with 5 positive, 28 negative and 2 flats
  • 7/10 - Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 7/9 – Wednesday closed positive with 28 positive, 5 negative and 2 flats
  • 7/8 - Tuesday closed positive with 22 positive, 10 negative and 3 flats
  • 7/7 – Monday closed negative with 6 positive, 27 negative and 2 flats
  • 7/4 – Friday market holiday
  • 7/3 – Thursday closed positive with 23 positive, 6 negative and 6 flats
  • 7/2 - Wednesday closed positive with 24 positive, 7 negative and 4 flats
  • 7/1 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/30 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Friday: Lenz Therapeutics (LENZ), Agenus (AGEN) and Mesoblast (MESO)
  • Thursday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and Blueprint Medicine (BPMC)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Tuesday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and Beam Therapeutics (BEAM)
  • Monday: Prime Medicine (PRME), AxoGen (AXGN) and MiMedx (MDXG)

The worst three (3) in the session: 

  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ultragenyx Pharmaceuticals (RARE)
  • Thursday: Ultragenyx Pharmaceuticals (RARE), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Wednesday: BioLife Solutions (BLFS), Harvard Apparatus RT (OTCQB: HRGN) and Brainstorm Cell Therapeutics (BCLI)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Agenus (AGEN)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.